AU2019338059B2 - Method of manufacturing a solid form of a bet bromodomain inhibitor - Google Patents
Method of manufacturing a solid form of a bet bromodomain inhibitor Download PDFInfo
- Publication number
- AU2019338059B2 AU2019338059B2 AU2019338059A AU2019338059A AU2019338059B2 AU 2019338059 B2 AU2019338059 B2 AU 2019338059B2 AU 2019338059 A AU2019338059 A AU 2019338059A AU 2019338059 A AU2019338059 A AU 2019338059A AU 2019338059 B2 AU2019338059 B2 AU 2019338059B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- solution
- cancer
- solvent
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730849P | 2018-09-13 | 2018-09-13 | |
| US62/730,849 | 2018-09-13 | ||
| PCT/IB2019/001011 WO2020053657A1 (en) | 2018-09-13 | 2019-09-13 | Method of manufacturing a solid form of a bet bromodomain inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019338059A1 AU2019338059A1 (en) | 2021-04-01 |
| AU2019338059B2 true AU2019338059B2 (en) | 2025-03-20 |
Family
ID=69777480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019338059A Active AU2019338059B2 (en) | 2018-09-13 | 2019-09-13 | Method of manufacturing a solid form of a bet bromodomain inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12145932B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3849980B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7731794B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210080373A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112955449B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019338059B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3111527A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202190598A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3034982T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL281258B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021002885A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202102497SA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI882964B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020053657A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥(上海)股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
| TW202327594A (zh) | 2021-09-23 | 2023-07-16 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 用bet溴結構域抑制劑和parp抑制劑的組合治療預選患者群體的三陰性乳腺癌的方法 |
| KR102619331B1 (ko) * | 2021-11-30 | 2023-12-29 | 주식회사 베노바이오 | Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015002754A2 (en) * | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN105473581B (zh) | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| CA2966452A1 (en) | 2014-12-17 | 2016-06-23 | Samuel David Brown | Substituted bicyclic compounds as bromodomain inhibitors |
| WO2017075377A1 (en) * | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CN109715625B (zh) * | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| WO2018097977A1 (en) | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| TWI816880B (zh) | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 治療前列腺癌之組合療法 |
| TWI841598B (zh) | 2018-09-13 | 2024-05-11 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 用於治療雌激素受體陽性乳癌之組合療法 |
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥(上海)股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
-
2019
- 2019-09-12 TW TW108133099A patent/TWI882964B/zh active
- 2019-09-13 EA EA202190598A patent/EA202190598A1/ru unknown
- 2019-09-13 ES ES19860308T patent/ES3034982T3/es active Active
- 2019-09-13 CA CA3111527A patent/CA3111527A1/en active Pending
- 2019-09-13 WO PCT/IB2019/001011 patent/WO2020053657A1/en not_active Ceased
- 2019-09-13 KR KR1020217010933A patent/KR20210080373A/ko active Pending
- 2019-09-13 US US17/275,465 patent/US12145932B2/en active Active
- 2019-09-13 IL IL281258A patent/IL281258B2/en unknown
- 2019-09-13 EP EP19860308.6A patent/EP3849980B1/en active Active
- 2019-09-13 JP JP2021514073A patent/JP7731794B2/ja active Active
- 2019-09-13 CN CN201980060128.8A patent/CN112955449B/zh active Active
- 2019-09-13 MX MX2021002885A patent/MX2021002885A/es unknown
- 2019-09-13 AU AU2019338059A patent/AU2019338059B2/en active Active
- 2019-09-13 SG SG11202102497SA patent/SG11202102497SA/en unknown
- 2019-09-13 EP EP25161539.9A patent/EP4588919A1/en active Pending
-
2024
- 2024-10-09 US US18/910,093 patent/US20250034142A1/en active Pending
-
2025
- 2025-08-20 JP JP2025137091A patent/JP2025179092A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015002754A2 (en) * | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4588919A1 (en) | 2025-07-23 |
| US20250034142A1 (en) | 2025-01-30 |
| EP3849980B1 (en) | 2025-04-23 |
| EP3849980A1 (en) | 2021-07-21 |
| TW202024078A (zh) | 2020-07-01 |
| IL281258B1 (en) | 2025-11-01 |
| CN112955449A (zh) | 2021-06-11 |
| JP2022500433A (ja) | 2022-01-04 |
| KR20210080373A (ko) | 2021-06-30 |
| WO2020053657A1 (en) | 2020-03-19 |
| US20220048905A1 (en) | 2022-02-17 |
| IL281258B2 (en) | 2026-03-01 |
| CA3111527A1 (en) | 2020-03-19 |
| MX2021002885A (es) | 2021-07-15 |
| TWI882964B (zh) | 2025-05-11 |
| SG11202102497SA (en) | 2021-04-29 |
| US12145932B2 (en) | 2024-11-19 |
| AU2019338059A1 (en) | 2021-04-01 |
| ES3034982T3 (en) | 2025-08-27 |
| JP7731794B2 (ja) | 2025-09-01 |
| JP2025179092A (ja) | 2025-12-09 |
| CN112955449B (zh) | 2025-04-29 |
| EA202190598A1 (ru) | 2021-08-02 |
| IL281258A (en) | 2021-04-29 |
| EP3849980A4 (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034142A1 (en) | Method of manufacturing a solid form of a bet bromodomain inhibitor | |
| WO2020053660A1 (en) | Solid forms of a bet inhibitor | |
| TWI697495B (zh) | 科帕利普(copanlisib)及其二鹽酸鹽之合成 | |
| EP3325485B1 (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| WO2011116634A1 (en) | Process and intermediates for preparing lapatinib | |
| CN114685531B (zh) | 四并环化合物及其药物组合物和应用 | |
| WO2022214645A1 (en) | Processes and intermediates for the preparation of relugolix | |
| AU2018213202B2 (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| JP7136527B2 (ja) | 3-[(3s)-7-ブロモ-2-オキソ-5-(ピリジン-2-イル)-2,3-ジヒドロ-1h-[1,4]-ベンゾジアゼピン-3-イル]プロピオン酸メチルエステルの調製方法及びその方法に有用な化合物 | |
| CA2648369A1 (en) | Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide | |
| EA043992B1 (ru) | Способ изготовления твердой формы ингибитора бромодомена bet | |
| HK40053356A (en) | Method of manufacturing a solid form of a bet bromodomain inhibitor | |
| WO2016071382A1 (en) | Synthesis of pi3k inhibitor and salts thereof | |
| HK40053356B (en) | Method of manufacturing a solid form of a bet bromodomain inhibitor | |
| EP4538259A1 (en) | Processes for the preparation of deucravacitinib | |
| JP7842890B2 (ja) | 4-[5-[ビス(2-クロロエチル)アミノ]-1-メチル-1H-ベンゾ[d]イミダゾール-2-イル]酪酸アルキルエステル及びホルミル化誘導体の調製方法 | |
| EP4512809A1 (en) | Method for producing 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative | |
| CN114591247A (zh) | 一种替莫唑胺中间体化合物 | |
| HK1252323B (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| WO2016071380A1 (en) | Synthesis of pi3k inhibitor and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |